Elsevier and IDBS announce Interoperability between IDBS E-WorkBook Suite and Reaxys®
Frankfurt, Germany and Guildford UK, February 1, 2011 – Elsevier, the world’s leading publisher of scientific content and solutions and IDBS, a global provider of innovative enterprise data management, analytics and modeling solutions, announced today that Reaxys is now interoperable with the IDBS E-WorkBook Suite. The partnership creates a new mechanism that integrates best-in-class chemistry content from journals and patents with documented proprietary scientific results.
E-WorkBook Suite offers a robust and easy-to-use data management solution that is used across R&D sectors. E-WorkBook users searching for relevant chemical data can smoothly transition into Reaxys, a workflow solution that provides extensive information on chemical compounds, related physical and pharmacological properties, and synthesis information, and then save their data and findings in their workflow. With Reaxys available via E-WorkBook, a new group of researchers can now access this extensive repository of experimentally validated data.
“There is a genuine need for automatically integrating relevant chemistry information directly into the research process,” said Neil Kipling, founder and CEO of IDBS. “Our partnership with Elsevier delivers essential chemical information to scientists just in time and at the point of use.”
Mark van Mierle, Managing Director of Elsevier Information Systems GmbH, added. ““Our customers want seamless, interoperable environments for their researchers. Our partnership with IDBS responds to customer needs and should further improve individual workflows and company productivity.”
“Bringing information together in a federated search reduces the time to make decisions on which molecule to make next,” said Robert Glen, Professor of Molecular Sciences Informatics at Cambridge University. “The integration of E-WorkBook and Reaxys provides an exciting new approach to improving productivity.”
The combination of E-WorkBook and Reaxys accelerates user workflows in the following ways:
• Pharmacokineticists can identify when metabolites have been mentioned in the published literature, and in turn identify a host of physical property data associated with the metabolites.
• Medicinal chemists working in drug design can rapidly compare in-house proprietary information with compounds reported in patents and journals.
• Synthetic chemists, who store their own chemistry preparation information in E-WorkBook, can compare it quickly against validated published literature and find optimal synthetic routes.
E-WorkBook-Reaxys interoperability is achieved by a customized API developed by the Reaxys team linking into the IDBS ScienceLink scientific content brokerage platform. IDBS and Elsevier will continue to work closely together to provide additional innovative content-related functions to Reaxys and E-WorkBook to significantly improve how researchers interact with the world’s best data.
IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, leaders in industrial chemistry, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.
IDBS’ Solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, high-tech materials and consumer products, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and products.
Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010. Further information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Vice President, Global Corporate Relations
Communications Director, IDBS
+1 908 429 2933